Honduras is an emerging Central American market with a recently strengthened medical device regulatory framework. Under Agreement No. 0631-ARSA-2023, the Agencia de Regulación Sanitaria (ARSA) now governs device sanitary control, and its National Center for Technovigilance (CNTV) handles post-market surveillance. Combined with ISO 14155 institutional ethics review and bioaccess® coordination, sponsors can generate FDA-submissible first-in-human data at ~30% lower cost than US/EU programs.
Honduras is an emerging Central American clinical research market that took a meaningful step forward in 2023 with a modernized medical device regulatory framework. Agreement No. 0631-ARSA-2023 — the Regulation for the Sanitary Control of Medical Devices — governs device registration and technovigilance under the Agencia de Regulación Sanitaria (ARSA); it is not a standalone clinical-trial regime.
For FIH device studies, the pathway combines ARSA authorization, institutional ethics committee approval, an investigational device import permit, and ISO 14155 / Declaration of Helsinki compliance. ARSA also houses a National Center for Technovigilance (CNTV), giving sponsors an established national channel for post-market device surveillance.
bioaccess® manages the complete pathway in Honduras — ARSA coordination, institutional ethics submissions, device import authorization, site qualification, and monitoring — so sponsors get FDA-quality first-in-human data at roughly 30% lower cost than a comparable US or EU program. Honduras is best positioned as part of a multi-country LATAM strategy or for programs where cost efficiency and Central American access matter.
The Agencia de Regulación Sanitaria (ARSA) is Honduras's national health regulation agency. For medical devices, Agreement No. 0631-ARSA-2023 governs device registration and technovigilance — not clinical-trial conduct directly. For FIH programs, sponsors must obtain ARSA authorization, institutional ethics committee approval, and an investigational device import permit before shipping product into the country. bioaccess® prepares ARSA-compliant submissions, secures the import permit, and coordinates with the agency throughout study start-up.
Clinical research in Honduras is reviewed by institutional ethics committees operating under ISO 14155 and the Declaration of Helsinki. Committees evaluate protocols for scientific merit, risk-benefit balance, informed consent adequacy, and patient protection. bioaccess® coordinates ethics submissions and manages responses to committee questions.
ARSA houses a National Center for Technovigilance (CNTV) responsible for post-market device surveillance in Honduras. This gives sponsors a defined national channel for adverse event reporting and post-market vigilance activities — a meaningful advantage for FIH programs that transition into commercial or post-market follow-up phases.
Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from Honduras for IDE submissions and marketing applications when studies are conducted under ISO 14155 with proper ARSA and ethics committee oversight. bioaccess® designs every protocol for FDA submission from day one, with source data verification and monitoring practices built around 21 CFR expectations.
| Metric | Honduras 🇭🇳 | United States 🇺🇸 | Europe (EU) 🇪🇺 |
|---|---|---|---|
| Medical device regulation | Agreement 0631-ARSA-2023 | 21 CFR 812 | EU MDR |
| Regulatory authority | ARSA (Agencia de Regulación Sanitaria) | FDA | EMA / national CAs |
| Ethics review | Institutional EC (ISO 14155 / Helsinki) | IRB | Per-country EC |
| Post-market surveillance | National Center for Technovigilance (CNTV) | MDR/MAUDE | EUDAMED / vigilance |
| FDA data acceptance | Eligible for submission/review — 21 CFR 812.28 (ISO 14155) | Native | Yes, with justification |
| Cost vs. US program | ~30% lower | Baseline | ~15–25% lower |
Regulatory details reflect published national frameworks; timelines and costs vary by device complexity, therapeutic area, and monitoring requirements. bioaccess® confirms the current pathway for each program.
The Agencia de Regulación Sanitaria (ARSA) is Honduras's health regulation agency and oversees medical devices under the Regulation for the Sanitary Control of Medical Devices, Agreement No. 0631-ARSA-2023.
Agreement No. 0631-ARSA-2023 is the Regulation for the Sanitary Control of Medical Devices — Honduras's framework for device registration and technovigilance under ARSA. It governs device oversight rather than clinical-trial conduct directly; FIH studies also require institutional ethics approval and an investigational device import permit.
ARSA houses a National Center for Technovigilance (CNTV) that handles medical device post-market surveillance, including adverse event reporting and vigilance activities.
Clinical research is reviewed by institutional ethics committees following ISO 14155 and the Declaration of Helsinki. bioaccess® coordinates ethics submissions and manages committee interactions.
Yes. Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from Honduras when studies are conducted under ISO 14155 with proper ARSA and institutional ethics oversight. bioaccess® designs protocols for FDA submission from the start.
Honduras offers a recently strengthened 2023 device regulatory framework, an established technovigilance channel via CNTV, and ~30% lower program cost than US or EU baselines. It's best positioned as part of a multi-country LATAM strategy or where Central American cost efficiency matters.
All countries we serve · Contact bioaccess® · First-in-Human CRO